scholarly journals Molecular mechanisms of epidermal growth factor receptor overexpression in patients with cervical cancer

2011 ◽  
Vol 24 (5) ◽  
pp. 720-728 ◽  
Author(s):  
Marlies Schrevel ◽  
Arko Gorter ◽  
Sandra M Kolkman-Uljee ◽  
J Baptist M Z Trimbos ◽  
Gert Jan Fleuren ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Molecular Mechanisms ◽  
Growth Factor Receptor ◽  
Epidermal Growth

Nuclear Y-box binding protein-1 expression as a prognostic marker and correlation with epidermal growth factor receptor expression in cervical cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 5085-5085
Author(s):  
Shin Nishio ◽  
Kimio Ushijima ◽  
Shuji Takemoto ◽  
Yuko Sasajima ◽  
Hitoshi Tsuda ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Her2 Expression ◽  
Stromal Invasion ◽  
Egfr Expression ◽  
Epidermal Growth ◽  
Poor Outcomes

5085 Background: Y-box binding protein-1 (YB-1) is a member of the cold shock protein family and functions in transcription and translation. Many reports indicate that YB-1 is highly expressed in tumor cells and is a marker of tumor aggressiveness and clinical prognosis. Overexpression of epidermal growth factor receptor (EGFR) has been associated with poor outcomes in cervical cancer (CC). Clinical trials have shown that EGFR inhibitors are effective against CC (JCO 2011). Nuclear YB-1 expression correlates with EGFR expression in various types of cancer. Methods: Nuclear YB-1 expression was immunohistochemically analyzed in tissue specimens obtained from 204 CC patients who underwent surgery. Associations of nuclear YB-1 expression with clinicopathological factors such as survival and EGFR (HER1 and HER2) expression were investigated. Results: Nuclear YB-1 expression was observed in 41 (20%) of 204 cases and correlated with stage, tumor diameter, stromal invasion, and lymph-node metastasis. Nuclear YB-1 expression also correlated with both HER1 expression (p=0.0114) and HER2 expression (p=0.0053). Kaplan-Meier survival analysis showed that nuclear YB-1 expression was significantly associated with poor outcomes in terms of progression-free survival (p=0.0033) and overall survival (p=0.0003). On multivariate analysis, stromal invasion, parametrial invasion, and nuclear YB-1 expression were independent predictors of survival. Conclusions: Nuclear YB-1 expression is a prognostic marker and correlates with EGFR expression in CC.

Epidermal Growth Factor Receptor Pathway Mutations and Colorectal Cancer Therapy

2011 ◽  
Vol 135 (10) ◽  
pp. 1278-1282 ◽  
Author(s):  
Allie H Grossmann ◽  
Wade S Samowitz
Keyword(s):  
Colorectal Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Molecular Analysis ◽  
Molecular Mechanisms ◽  
Growth Factor Receptor ◽  
Treatment Decisions ◽  
Molecular Testing ◽  
Epidermal Growth

Context.—Rational anticancer therapy is beginning to expand the practice of surgical pathology beyond a primarily morphologic and immunophenotypic analysis into the molecular arena. Molecular testing of tumors can have both diagnostic and therapeutic value, which guides treatment decisions. This is true for colorectal cancer in which mutations in signaling mediators predict resistance to anti–epidermal growth factor receptor (anti-EGFR) therapy. Objective.—To review the clinically relevant mutations that currently guide treatment decisions in metastatic colorectal cancer, summarize additional mutations that are expected to improve the prognostic sensitivity of molecular testing, and provide practical suggestions for submitting specimens for molecular analysis. Data Sources.—Peer-reviewed literature reporting pertinent clinical trial data, mutation analysis, and molecular mechanisms of drug resistance, as well as comprehensive review articles germane to the topic and published testing recommendations from the College of American Pathologists. Conclusions.—Molecular analysis of colorectal cancer is now mandated before initiation of anti-EGFR therapy and directly impacts treatment options and outcomes. Familiarity with the mutations that determine utility and efficacy of therapy, as well as the importance of careful sample selection, will facilitate appropriate testing and optimize patient care.

Detection of epidermal growth factor receptor mRNA in peripheral blood of cervical cancer patients

2003 ◽  
Vol 89 (3) ◽  
pp. 480-485 ◽  
Author(s):  
Akira Mitsuhashi ◽  
Naotake Tanaka ◽  
Kiyomi Suzuka ◽  
Hideo Matsui ◽  
Katsuyoshi Seki ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
Growth Factor Receptor ◽  
Receptor Mrna ◽  
Epidermal Growth
Sign in / Sign up

Export Citation Format

Share Document